Abstract
Biotechnology Law ReportVol. 38, No. 2 As presented by Chris HolmanMomenta Pharm., Inc. v. Bristol-Myers Squibb Co. United States Court of Appeals of the Federal Circuit, 2019 915 F.3d 764Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMAN*Published Online:15 Apr 2019https://doi.org/10.1089/blr.2019.29113.cmhAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byDrug Repurposing for Rare Diseases: A Role for Academia20 October 2021 | Frontiers in Pharmacology, Vol. 12 Volume 38Issue 2Apr 2019 InformationCopyright 2019, Mary Ann Liebert, Inc., publishersTo cite this article:Momenta Pharm., Inc. v. Bristol-Myers Squibb Co. United States Court of Appeals of the Federal Circuit, 2019 915 F.3d 764.Biotechnology Law Report.Apr 2019.131-134.http://doi.org/10.1089/blr.2019.29113.cmhPublished in Volume: 38 Issue 2: April 15, 2019PDF download
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
